Every GLP-1 Medication in 2026

Complete reference of all approved and pipeline GLP-1 receptor agonists, dual agonists, and triple agonists — with dosing schedules, half-life data, and clinical trial weight loss results.

FDA-Approved Medications

Semaglutide

Ozempic · Wegovy · Rybelsus

GLP-1 Agonist
Route: both
Frequency: Weekly (injection) / Daily (oral)
Half-life: 7 days
Weight loss: ~15-16%

Tirzepatide

Mounjaro · Zepbound

Dual GLP-1/GIP Agonist
Route: injectable
Frequency: Weekly
Half-life: 5 days
Weight loss: ~20-22.5%

Liraglutide

Victoza · Saxenda

GLP-1 Agonist
Route: injectable
Frequency: Daily
Half-life: 0.5 days
Weight loss: ~9%

Dulaglutide

Trulicity

GLP-1 Agonist
Route: injectable
Frequency: Weekly
Half-life: 5 days
Weight loss: ~3-5%

Exenatide

Byetta · Bydureon

GLP-1 Agonist
Route: injectable
Frequency: Twice daily (Byetta) / Weekly (Bydureon)
Half-life: 0.1 days
Weight loss: ~3-4%

Lixisenatide

Adlyxin · Lyxumia

GLP-1 Agonist
Route: injectable
Frequency: Daily
Half-life: 0.1 days
Weight loss: ~2-3%

Mazdutide

Mazdutide

Dual GLP-1/Glucagon Agonist
Route: injectable
Frequency: Weekly
Half-life: 6 days
Weight loss: ~20% at 60 weeks

Approved in China. GLORY-2 trial showed ~20% weight loss. Global trials pending.

Pipeline & Investigational

CagriSema

CagriSema

GLP-1 + Amylin Combination
Route: injectable
Frequency: Weekly
Half-life: 7 days
Weight loss: ~22.7%

Combination of semaglutide 2.4mg + cagrilintide 2.4mg. REDEFINE 1 Phase 3 complete.

Orforglipron

Orforglipron

GLP-1 Agonist
Route: oral
Frequency: Daily
Half-life: 1.2 days
Weight loss: ~8-9% at 6 months

First non-peptide oral GLP-1. No fasting required. NDA submitted to FDA.

Retatrutide

Retatrutide

Triple Agonist (GLP-1/GIP/Glucagon)
Route: injectable
Frequency: Weekly
Half-life: 5 days
Weight loss: ~24.2% at 48 weeks

Triple agonist. Highest weight loss observed in any trial. Phase 3 ongoing.

Survodutide

Survodutide

Dual GLP-1/Glucagon Agonist
Route: injectable
Frequency: Weekly
Half-life: 6.5 days
Weight loss: Phase 3 ongoing (SYNCHRONIZE trials)

Dual GLP-1/glucagon agonist. Strong liver fat reduction. SYNCHRONIZE Phase 3 ongoing.

VK2735

VK2735

Dual GLP-1/GIP Agonist
Route: both
Frequency: Weekly (SC) / Daily (oral)
Half-life: 5 days
Weight loss: ~14.7% at 13 weeks (SC)

Dual GLP-1/GIP. Both injectable and oral forms in development. VANQUISH Phase 3 ongoing.

Pemvidutide

Pemvidutide

Dual GLP-1/Glucagon Agonist
Route: injectable
Frequency: Weekly
Half-life: 6 days
Weight loss: ~6.2% at 24 weeks

MASH-focused. Notable for very low discontinuation rates (0-1.2%). IMPACT trial.

Cagrilintide

Cagrilintide

GLP-1 + Amylin Combination
Route: injectable
Frequency: Weekly
Half-life: 7 days
Weight loss: ~11.8% (monotherapy)

Long-acting amylin analog. Part of CagriSema combination. Also studied as monotherapy.

Track any of these medications with DoseCurve

Log injections, visualize blood levels, and see your progress over time.

Start tracking free